RXDX-106 Is an orally-available, potent and selective TAM/MET inhibitor demonstrating preclinical efficacy in MET-dependent human malignancies
Aleksandra Franovic(Ondine Biopharma (United States)), Estelle Martin, A. Albert, Sean Uryu(Pfizer (United States)), Guodong Li(University of Macau), Markus Falk, Annelie Schairer
Cited by 2
Related Papers
VEGF-Induced Vascular Permeability Is Mediated by FAK
|Developmental Cell|2012|339
Identification of a GABA <sub>A</sub> Receptor Anesthetic Binding Site at Subunit Interfaces by Photolabeling with an Etomidate Analog
|Journal of Neuroscience|2006|290
FAK promotes recruitment of talin to nascent adhesions to control cell motility
|The Journal of Cell Biology|2012|218
PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility
|The Journal of Cell Biology|2008|213